Teva Pharmaceutical Industries Limited Seeks To Outbid Rival Endo Health Solutions Inc. With $114 Million NuPathe Inc. Offer
Published: Jan 08, 2014
Teva Pharmaceutical Industries Ltd. (TEVA) offered at least $114 million to acquire U.S. migraine treatment maker NuPathe Inc. (PATH:US), seeking to outbid a previous offer from Endo Health Solutions Inc. (ENDP:US) Teva offered to pay $3.65 a share, plus as much as $3.15 a share if sales goals are achieved related to the migraine drug Zecuity, NuPathe said today in a corporate filing (PATH:US). Endo’s offer, announced Dec. 16, was for $105 million in cash plus as much as $3.15 per share in milestone payments.
Help employers find you! Check out all the jobs and post your resume.